Competing interests
NSCLC, SCLC, urothelial cancer, MDM, urothelial carcinoma, lung cancer, HCC, pembrolizumab in hepatocellular carcinoma
NON-SMALL CELL LUNG CANCER, SCLC, UROTHELIAL CARCINOMA, LUNG CANCER, HEPATOCELLULAR CARCINOMA, PANCREATIC CANCER, BLADDER CANCER, NSCLC, PROSTATE CANCER, HORMONE-SENSITIVE PROSTATE CANCER
AS1 reports honoraria from Eli Lilly, MSD, and Janssen and travel support from Bristol-Myers Squibb and AstraZeneca. MDM reports the following COIs: AstraZeneca, advisory board, personal, and consultancy about the role of osimertinib as adjuvant treatment of NSCLC; Boehringer Ingelheim, invited speaker, personal, and compensation for a talk and a document about the role of patient-reported outcomes in clinical trials and in clinical practice, with a specific focus on lung cancer; Janssen, advisory board, personal, and advisory board about the role of chemotherapy and hormonal treatment in hormone-sensitive prostate cancer; Merck Serono, advisory board, personal, consultant for the new indication of avelumab in urothelial cancer; Merck Sharp & Dohme, advisory board, personal, participation in advisory boards about olaparib in pancreatic cancer, about olaparib in prostate cancer, and about immunotherapy in lung cancer; Novartis, advisory board, personal, and consultancy about clinical trial methodology and clinical trial results interpretation; Pfizer, advisory board, personal, and consultancy about the results obtained with lorlatinib and dacomitinib in advanced non-small cell lung cancer; Roche, advisory board, personal, and consultancy about immunotherapy in SCLC; Takeda, advisory board, personal, and consultancy about role and interpretation of the patient-reported outcomes and quality of life in clinical trials; Beigene, local PI, onstitutional, and local PI of trial with tislelizumab in hepatocellular carcinoma; Exelixis, local PI, institutional, and local PI of a trial with cabozantinib and atezolizumab in advanced HCC; Merck Sharp & Dohme, local PI, institutional, and local PI of trials with pembrolizumab in hepatocellular carcinoma; Pfizer, local PI, institutional, and local PI of a trial with sasanlimab in NMI bladder cancer; Roche, local PI, institutional, and local PI of a trial with atezolizumab and bevacizumab in advanced HCC; Tesaro—GlaxoSmithKline, research grant, institutional, and financial support and drug supply for the Meet-URO12 trial (niraparib as maintenance treatment of urothelial carcinoma after first-line treatment with platinum-based chemotherapy). RB reports honoraria from BMS, MSD, AstraZeneca, Lilly, Roche, and Novartis.